Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.

Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) is scheduled for September 4-7, 2024 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2024 offers in-person, virtual and on-demand participation.

Register Now
  • 8,025 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 8,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

What are the Controversies Surrounding MRD in Blood Cancers

Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.

Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML

Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction.

Get to Know … Julie Vose, MD, MBA

Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.

What to Know About Monoclonal B-Cell Lymphocytosis From Paolo Ghia, MD, PhD

Dr. Ghia, a Professor of Medicine and Director of Strategic Research on CLL at the Università Vita-Salute San Raffaele in Italy, talks about his session on monoclonal B-cell lymphocytosis at the 2024 AACR Meeting.

Study Identifies Features that Predict Follicular Lymphoma Early Relapse

Tumor cells in high-risk follicular lymphoma had enhanced B-cell receptor signaling and distinct follicular growth patterns.

Sundar Jagannath, MBBS, on Linvoseltamab in Relapsed or Refractory Myeloma

The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top